William F. Mieler

William F. Mieler

Auto-generated profile, based on publicly available information

William F. Mieler

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2020 in Eye
Verified
Journal Article
Closed access
JKJennifer J. Kang-Mieler
Jennifer J. Kang-Mieler
KRKayla M. Rudeen
Kayla M. Rudeen
WLWenqiang Liu
Wenqiang Liu
WMWilliam F. Mieler
William F. Mieler

1 January 2017 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
YJYi Jiang
Yi Jiang
WMWilliam F. Mieler
William F. Mieler
The Asia-Pacific Journal of Ophthalmology (APJO) is the official publication of the Asia-Pacific Academy of Ophthalmology. The APJO positions itself as a first-class bimonthly (6 issues per year) peer-viewed e-journal representative of ophthalmic and visual science developments in the Asia-Pacific region. The APJO welcomes the submission of original, previously unpublished manuscripts which describe clinical investigations, clinical observations and clinically relevant laboratory investigations.

24 March 2023 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
SSSwathi Somisetty
Swathi Somisetty
ASAhmad Santina
Ahmad Santina
DSDavid Sarraf
David Sarraf
WMWilliam F. Mieler
William F. Mieler
This study will provide a thorough review of systemic (and select intravitreal) medications, along with illicit drugs that are capable of causing various patterns of retinal toxicity. The diagnosis is established by taking a thorough medication and drug history, and then by pattern recognition of the clinical retinal changes and multimodal imaging features. Examples of all of these types of toxicity will be thoroughly reviewed, including agents that cause retinal pigment epithelial disruption (hydroxychloroquine, thioridazine, pentosan polysulfate sodium, dideoxyinosine), retinal vascular occlusion (quinine, oral contraceptives), cystoid macular edema/retinal edema (nicotinic acid, sulfa-containing medications, taxels, glitazones), crystalline deposition (tamoxifen, canthaxanthin, methoxyflurane), uveitis, miscellaneous, and subjective visual symptoms (digoxin, sildenafil). The impact of newer chemotherapeutics and immunotherapeutics (tyrosine kinase inhibitor, mitogen-activated protein kinase kinase, checkpoint, anaplastic lymphoma kinase, extracellular signal-regulated kinase inhibitors, and others), will also be thoroughly reviewed. The mechanism of action will be explored in detail when known. When applicable, preventive measures will be discussed, and treatment will be reviewed. Illicit drugs (cannabinoids, cocaine, heroin, methamphetamine, alkyl nitrite), will also be reviewed in terms of the potential impact on retinal function.

4 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EDEmily Dosmar
Emily Dosmar
GVGabrielle Vuotto
Gabrielle Vuotto
XSXingqi Su
Xingqi Su
EREmily Roberts
Emily Roberts
ALAbigail Lannoy
Abigail Lannoy
JKJennifer J. Kang-Mieler
Jennifer J. Kang-Mieler
The purpose of this study was to examine antibiotic drug transport from a hydrogel drug delivery system (DDS) using a computational model and a 3D model of the eye. Hydrogel DDSs loaded with vancomycin (VAN) were synthesized and release behavior was characterized in vitro. Four different compartmental and four COMSOL models of the eye were developed to describe transport into the vitreous originating from a DDS placed topically, in the subconjunctiva, subretinally, and intravitreally. The concentration of the simulated DDS was assumed to be the initial concentration of the hydrogel DDS. The simulation was executed over 1500 and 100 h for the compartmental and COMSOL models, respectively. Based on the MATLAB model, topical, subconjunctival, subretinal and vitreous administration took most (~500 h to least (0 h) amount of time to reach peak concentrations in the vitreous, respectively. All routes successfully achieved therapeutic levels of drug (0.007 mg/mL) in the vitreous. These models predict the relative build-up of drug in the vitreous following DDS administration in four different points of origin in the eye. Our model may eventually be used to explore the minimum loading dose of drug required in our DDS leading to reduced drug use and waste.

1 November 1995 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
WMWilliam F. Mieler
William F. Mieler
SNSumit K. Nanda
Sumit K. Nanda
MWMitchell D. Wolf
Mitchell D. Wolf
JHJoseph Harman
Joseph Harman
Research from JAMA Ophthalmology — Golf-Related Ocular Injuries

12 July 2012 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
DKDaniel F Kiernan
Daniel F Kiernan
WMWilliam F Mieler
William F Mieler
Introduction: Diabetic macular edema (DME), cystoid macular edema (CME), age-related macular degeneration (AMD), retinal vascular occlusion (RVO) and uveitis are responsible for severe visual impairment worldwide. In some patients with these conditions, treatment with intraocular corticosteroids may be beneficial. Although off-label use of these agents has occurred for many years, novel agents including preservative-free and sustained-release intravitreal implants are currently being studied in clinical trials (CTs). Areas covered: This paper reviews the use of CTs for vitreoretinal (VR) diseases including choroidal neovascularization, CME, DME, RVO and posterior uveitis. It also discusses the use of corticosteroids for treating VR disease, including dexamethasone, fluocinolone acetonide, intravitreal implants and triamcinolone acetonide. Expert opinion: Used alone, intravitreal corticosteroids may benefit disorders such as DME, RVO and uveitis compared with standard therapy. Cases of exudative AMD non-responsive to standard treatment may benefit from combination therapy, including usage of intravitreal corticosteroid injections. Intraoperative use of these agents may aid visualization of retinal structures. Sustained-release intraocular implants have been approved for posterior uveitis and RVO associated with macular edema. In spite of this, most intraocular corticosteroids have a limited duration of action along with significant side effects, including cataract and glaucoma. Currently, intravitreal corticosteroid usage for DME is considered off-label.